Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7715MR)

This product GTTS-WQ7715MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7715MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14272MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ15569MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ268MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ11615MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ6765MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ8862MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ1603MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ13640MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA R4930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW